Journal of Endocrinological Investigation

, Volume 14, Issue 9, pp 757–762 | Cite as

CV 205–502 treatment of macroprolactinomas

  • B. Crottaz
  • A. Uske
  • M. J. Reymond
  • F. Rey
  • R. A. Siegel
  • J. Brownell
  • F. Gomez


CV 205–502, a benzoquinoline, is a new nonergot dopamine agonist compound which has been shown to be effective in lowering PRL levels in normal volunteers and in hyperprolactinemic women. Seven patients (4 men and 3 women) presenting with hyperprolactinemia due to macroprolactinoma were treated with CV 205–502 given as a single daily dose at bedtime for up to 12 months. Six patients presented with impaired gonadal function and 2 with galactorrhea. All patients but one had previously been treated with bromocriptine and 4 had undergone pituitary surgery (3 with complementary radiotherapy). Six patients responded within a few weeks to CV 205–502 treatment, PRL levels being normalized (4 patients, 0.075 to 0.150 mg/day) or significantly reduced to restore normal gonadal function (2 patients, 0.225 mg/day). The seventh patient, who had previously been resistant to bromocriptine, also failed to respond to CV 205–502 treatment even after high doses (0.450 mg/day). Under CV 205–502 treatment, follow-up with magnetic resonance imaging revealed a reduction in tumor size of up to 52% of the initial volume in the “PRL-responders” whereas an increase in tumor size was observed in the “nonresponding” patient. No biological disturbance appeared during CV 205–502 treatment and the drug tolerance was very good, with mild side-effects being reported by only 2 patients. In conclusion, CV 205–502, given once daily, appears to be a safe and effective alternative to other dopamine agonists in the treatment of macroprolactinoma, by reducing hyperprolactinemia and tumor size. It was, however, of no benefit in the one patient whose macroprolactinoma had been resistant to bromocriptine.


Hyperprolactinemia pituitary neoplasms dopaminergic drugs 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Vance M.L., Evans W.S., Thorner M.O. Diagnosis and treatment. Drugs five years later: bromocriptine. Ann. Intern. Med. 100: 78, 1984.PubMedCrossRefGoogle Scholar
  2. 2.
    Liuzzi A., Dallabonzana D., Oppizzi G., Verde G.G., Cozzi R., Chiodini P., Luccarelli G. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N. Engl. J. Med. 313: 656, 1985.PubMedCrossRefGoogle Scholar
  3. 3.
    Ciccarelli E., Miola C., Avataneo T., Camanni F., Besser G.M., Grossman A. Long-term treatment with a new repeatable injectable form of bromocriptine, Parlodel LAR®, in patients with tumorous hyperprolactinemia. Fertil. Steril. 52: 930, 1989.PubMedGoogle Scholar
  4. 4.
    Kocijancic A., Prezelj J., Vrhovec I., Lancranjan I. Parlodel LAR® in the treatment of macroprolactinomas. Acta Endocrinol. (Copenh) 122: 272, 1990.Google Scholar
  5. 5.
    Molitch M.E., Elton R.L., Blackwell R.E., Caldwell B., Chang R.J., Jaffe R., Joplin G., Robbins R.J., Tyson J., Thorner M.O. and the Bromocriptine Study Group. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J. Clin. Endocrinol. Metab. 60: 698, 1985.PubMedCrossRefGoogle Scholar
  6. 6.
    Closse A., Camps M., Wanner A., Palacios J.M. In vivo labeling of brain dopamine D2 receptors using the high-affinity specific D2 agonist [3H] CV 205–502. Brain Res. 440: 123, 1988.PubMedCrossRefGoogle Scholar
  7. 7.
    Rasmussen C., Bergh T., Wide L., Brownell J. CV 205–502: a new long-acting drug for inhibition of prolactin hypersecretion. Clin. Endocrinol. (Oxf.) 26: 321, 1987.CrossRefGoogle Scholar
  8. 8.
    Gaillard R.C., Brownell J. Hormonal effects of CV 205–502, a novel octahydrobenzo[g]quinoline with potent dopamine agonist properties. Life Sci. 43: 1355, 1988.PubMedCrossRefGoogle Scholar
  9. 9.
    Vance M.L., Cragun J.R., Reimnitz C., Chang R.J., Rashef E., Blackwell R.E., Miller M.M., Molitch M.E. CV 205–502 treatment of hyperprolactinemia. J. Clin. Endocrinol. Metab. 68: 336, 1989.PubMedCrossRefGoogle Scholar
  10. 10.
    van der Heijden P.F.M., Lappohn R.E., Corbey R.S., de Goeij W.B.K.M.V., Brownell J., Rolland R. The effectiveness, safety, and tolerability of CV 205–502 in hyperprolactinemic women: a 12-month study. Fertil. Steril. 52: 574, 1989.PubMedGoogle Scholar
  11. 11.
    Rasmussen C., Bergh T., Wide L., Brownell J. Long-term treatment with a new non-ergot long-acting dopamine agonist, CV 205–502, in women with hyperprolactinaemia. Clin. Endocrinol. (Oxf.). 29: 271, 1988.PubMedCrossRefGoogle Scholar
  12. 12.
    Newman C.B., Hurley A.M., Kleinberg D.L. Effect of CV 205–502 in hyperprolactinaemic patients intolerant of bromocriptine. Clin. Endocrinol. (Oxf.). 31: 391, 1989.PubMedCrossRefGoogle Scholar
  13. 13.
    Homburg R., West C., Brownell J., Jacobs H.S. A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205–502, with bromocriptine in women with hyperprolactinaemia. Clin. Endocrinol. (Oxf.). 32: 565, 1990.PubMedCrossRefGoogle Scholar
  14. 14.
    Khalfallah Y., Claustrat B., Grochowicki M., Flocard F., Horlait S., Serusclat P., Sassolas G. Effects of new prolactin inhibitor, CV 205–502, in the treatment of human macroprolactinomas. J. Clin. Endocrinol. Metab. 71: 354, 1990.PubMedCrossRefGoogle Scholar
  15. 15.
    Van’t Verlaat J.W., Croughs R.J.M., Brownell J. Treatment of macroprolactinomas with a new non-ergot, long-acting dopaminergic drug, CV 205–502. Clin. Endocrinol. (Oxf.) 33: 619, 1990.CrossRefGoogle Scholar
  16. 16.
    Serri O., Beauregard H., Lesage J., Pedneault L., Comtois R., Jilwan N., Somma M., Vachon L., Brownell J. Long term treatment with CV 205–502 in patients with prolactin-secreting pituitary macroadenomas. J. Clin Endocrinol. Metab. 71: 682, 1990.PubMedCrossRefGoogle Scholar
  17. 17.
    Barnett P.S., Dawson J.M., Butler J., Coskeran P.B., Maccabe J.J., McGregor A.M. CV 205–502, a new non-ergot dopamine agonist, reduces prolactinoma size in man. Clin. Endocrinol. (Oxf.) 33: 307, 1990.CrossRefGoogle Scholar
  18. 18.
    Vance M.L., Lipper M., Klibanski A., Biller B.M., Samaan N.A., Molitch M.E. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205–502. Ann. intern. Med. 112: 668, 1990.PubMedCrossRefGoogle Scholar
  19. 19.
    Duranteau L., Chanson P., Lavoinne A., Horlait S., Lubetzki J., Kuhn J.M. Effect of the new dopaminergic agonist CV 205–502 on plasma prolactin levels and tumor size in bromocriptine-resistant prolactinomas. Clin. Endocrinol. (Oxf.) 34: 25, 1991.CrossRefGoogle Scholar
  20. 20.
    Kucharczyk W. The pituitary gland and sella turcica. In: Brant-Zawadzki M., Norman D. (Eds), Magnetic resonance imaging of the central nervous system. Raven Press, New York, 1987, p. 187.Google Scholar
  21. 21.
    Rey F, Valterio C., Locatelli L., Ramelet A.A., Felber J.P. Lack of endocrine systemic side effects after topical application of spironolactone in man. J. Endocrinol. Invest. 11: 273, 1988.PubMedGoogle Scholar
  22. 22.
    Pellegrini I., Rasolonjanahary R., Gunz G., Delivet B.S., Jedynak C.P., Kordon C., Peilion F., Jaquet P., Enjalbert A. Resistance to bromocriptine in prolactinomas. J. Clin. Endocrinol. Metab. 69: 500, 1989.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1991

Authors and Affiliations

  • B. Crottaz
    • 1
  • A. Uske
    • 2
  • M. J. Reymond
    • 1
  • F. Rey
    • 1
  • R. A. Siegel
    • 3
  • J. Brownell
    • 3
  • F. Gomez
    • 1
  1. 1.Division d’Endocrinologie et Biochimie Clinique, Département de Médecine InterneCHUV-BH 10LausanneSwitzerland
  2. 2.Service de RadiodiagnosticCHUVLausanneSwitzerland
  3. 3.Clinical Research, Sandoz Ltd.Bern and BasleSwitzerland

Personalised recommendations